LLY

974.96

-1.19%↓

JNJ

222.47

-0.89%↓

ABBV

202.58

-1.21%↓

UNH

369.71

+0.7%↑

AZN

182.23

-1.36%↓

LLY

974.96

-1.19%↓

JNJ

222.47

-0.89%↓

ABBV

202.58

-1.21%↓

UNH

369.71

+0.7%↑

AZN

182.23

-1.36%↓

LLY

974.96

-1.19%↓

JNJ

222.47

-0.89%↓

ABBV

202.58

-1.21%↓

UNH

369.71

+0.7%↑

AZN

182.23

-1.36%↓

LLY

974.96

-1.19%↓

JNJ

222.47

-0.89%↓

ABBV

202.58

-1.21%↓

UNH

369.71

+0.7%↑

AZN

182.23

-1.36%↓

LLY

974.96

-1.19%↓

JNJ

222.47

-0.89%↓

ABBV

202.58

-1.21%↓

UNH

369.71

+0.7%↑

AZN

182.23

-1.36%↓

Kodu・Aktsiate loetelu・Lantheus Holdings Inc

Lantheus Holdings Inc

Suletud

SektorTervishoid

90.99 5.75

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

85.66

Max

92.65

Põhinäitajad
By Trading Economics
Sissetulek	26M 54M
Müük	23M 407M
P/E Sektori keskmine	25.08 49.8
Kasumimarginaal	13.296
Töötajad	1,193
EBITDA	31M 98M

Soovitused
By TipRanks
Soovitused	Tugev "osta" hinnang
12 kuu keskmine prognoos	+10.27% upside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	5. aug 2026

Turustatistika
By TradingEconomics
Turukapital	723M 5.7B
Eelmine avamishind	85.24
Eelmine sulgemishind	90.99

Uudiste sentiment

By Acuity

25%

75%

55 / 347 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Very Strong Bearish Evidence

79.24 / 103.64 Toetus ja vastupanu

Lantheus Holdings Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

7. mai 2026, 23:58 UTC

Tulu

OCBC's First-Quarter Net Profit Rose on Record Noninterest Income

7. mai 2026, 22:57 UTC

Tulu

Australia's Macquarie Beats Consensus With 30% Fiscal Year Profit Jump

7. mai 2026, 23:52 UTC

Tulu

CoreWeave Stock Dives on Weak Outlook -- Barrons.com

7. mai 2026, 23:45 UTC

Market Talk

Nikkei May Decline Amid Middle East Uncertainty -- Market Talk

7. mai 2026, 23:39 UTC

Market Talk

Gold Rises on Signs of Ongoing U.S.-Iran Tensions -- Market Talk

7. mai 2026, 23:28 UTC

Market Talk

Australian Budget Set to Contain A$64B in Spending Cuts-- Market Talk

7. mai 2026, 23:11 UTC

Tulu

OCBC Group CEO: Well-Positioned to Navigate Uncertainties, Deliver Sustainable Long-Term Value >O39.SG

7. mai 2026, 23:06 UTC

Tulu

Oversea-Chinese Banking Corp. 1Q Net Interest Margin 1.76%, Down 28 Bps on Year >O39.SG

7. mai 2026, 23:05 UTC

Tulu

Oversea-Chinese Banking Corp.: Solid 1Q Performance Underpinned by Record Non-Interest Income >O39.SG

7. mai 2026, 23:04 UTC

Tulu

Oversea-Chinese Banking Corp. 1Q Non-Interest Income S$1.61B Vs. S$1.31B >O39.SG

7. mai 2026, 23:03 UTC

Tulu

Oversea-Chinese Banking Corp. 1Q Net Interest Income S$2.22B Vs. S$2.35B >O39.SG

7. mai 2026, 23:03 UTC

Tulu

Oversea-Chinese Banking Corp. 1Q Net S$1.97B Vs. Net S$1.88B >O39.SG

7. mai 2026, 23:02 UTC

Tulu

Oversea-Chinese Banking Corp. 1Q Total Income S$3.83B Vs. S$3.66B >O39.SG

7. mai 2026, 23:00 UTC

Market Talk

Australia's Federal Budget Likely to Contain Significant Reforms -- Market Talk

7. mai 2026, 22:45 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

7. mai 2026, 22:45 UTC

Market Talk

Lyft Says Efforts to Service Waymo's AVs Are Underway -- Market Talk

7. mai 2026, 22:42 UTC

Tulu

Australia's Macquarie Beats Consensus With 30% FY Profit Jump

7. mai 2026, 22:33 UTC

Tulu

Omandamised, ülevõtmised, äriostud

Gilead Stock Falls. A Massive Acquisition Spree Is Coming at a Cost. -- Barrons.com

7. mai 2026, 22:32 UTC

Tulu

Macquarie FY Total Customer Deposits A$221.5B Vs. A$177.7B>MQG.AU

7. mai 2026, 22:31 UTC

Tulu

Macquarie FY Return on Equity 14.0% Vs. 11.2%>MQG.AU

7. mai 2026, 22:31 UTC

Tulu

Macquarie: 68% of FY Income From International >MQG.AU

7. mai 2026, 22:30 UTC

Tulu

Macquarie Bank Year-End CET1 Level 2 Ratio 12.8%>MQG.AU

7. mai 2026, 22:30 UTC

Tulu

Macquarie Capital Surplus A$9.3B at March 31 Vs. A$9.5B a Year Earlier>MQG.AU

7. mai 2026, 22:29 UTC

Tulu

Macquarie CEO: Well-Positioned for Superior Medium-Term Performance>MQG.AU

7. mai 2026, 22:28 UTC

Tulu

Macquarie: Continues a Conservative Approach to Capital, Funding, Liquidity>MQG.AU

7. mai 2026, 22:28 UTC

Tulu

Macquarie: Continues to Maintain a Cautious Stance>MQG.AU

7. mai 2026, 22:27 UTC

Tulu

Macquarie: Decision Recognizes Prevailing Market Conditions>MQG.AU

7. mai 2026, 22:27 UTC

Tulu

Macquarie Has Not Purchased Shares Since Extending the Buyback>MQG.AU

7. mai 2026, 22:26 UTC

Tulu

Macquarie to End Share Buyback Extended in November>MQG.AU

7. mai 2026, 22:25 UTC

Tulu

Macquarie Commodities and Global Markets FY Net Profit Contribution A$4.2B, Up 49% on Year>MQG.AU

Võrdlus sarnastega

Hinnamuutus

Lantheus Holdings Inc Prognoos

Hinnasiht

By TipRanks

10.27% tõus

12 kuu keskmine prognoos

Keskmine 95 USD 10.27%

Kõrge 110 USD

Madal 85 USD

Põhineb 8 Wall Streeti analüütiku instrumendi Lantheus Holdings Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

8 ratings

Osta

Hoia

Müü

Põhineb 8 analüütiku instrumendi Lantheus Holdings Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

79.24 / 103.64Toetus ja vastupanu

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

The bullish and bearish events are balanced.

Sentiment

By Acuity

55 / 347 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Lantheus Holdings Inc

Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer. The company also offers Automated Bone Scan Index that calculates the disease burden of prostate cancer by detecting and classifying bone scan tracer uptakes as metastatic or benign lesions using an artificial neural network; RELISTOR for opioid-induced constipation; and aPROMISE, an artificial intelligence medical device software; and PYLARIFY AI, an AI-based medical device software to perform quantitative assessment of PSMA PET/CT images in prostate cancer. In addition, it develops 1095, a PSMA-targeted iodine-131-labeled small molecule; PNT2002, a radiopharmaceutical therapy to treat mCRPC; PNT2003, an SSTR therapy that treats patients with SSTR-positive neuroendocrine tumors; MK-6240, a F 18-labeled PET imaging agent that targets Tau tangles in Alzheimer's disease; LNTH-1363S, an fibroblast activation protein, alpha targeted, copper-64 labeled PET imaging agent; and flurpiridaz used to assess blood flow to the heart;. It has collaboration agreements with GE Healthcare; NanoMab Technology Limited; Curium; RefleXion Medical, Inc.; POINT; Regeneron Pharmaceuticals, Inc; and Ratio Therapeutics LLC. The company was founded in 1956 and is based in Bedford, Massachusetts.